Transatlantique Private Wealth LLC Reduces Position in CVS Health Corporation $CVS

Transatlantique Private Wealth LLC trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 22.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,729 shares of the pharmacy operator’s stock after selling 2,195 shares during the quarter. Transatlantique Private Wealth LLC’s holdings in CVS Health were worth $533,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. increased its position in shares of CVS Health by 0.8% during the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after acquiring an additional 969,027 shares during the last quarter. Dodge & Cox increased its position in shares of CVS Health by 4.8% during the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after acquiring an additional 3,353,223 shares during the last quarter. Invesco Ltd. increased its position in shares of CVS Health by 13.2% during the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after acquiring an additional 2,375,764 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in CVS Health by 14.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock valued at $1,037,205,000 after buying an additional 1,942,886 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in CVS Health by 5.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock valued at $924,643,000 after buying an additional 728,924 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CVS. Cantor Fitzgerald upped their target price on CVS Health from $78.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Royal Bank Of Canada upped their target price on CVS Health from $81.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. UBS Group upped their price target on CVS Health from $79.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Barclays raised their price objective on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Finally, Morgan Stanley lifted their price objective on CVS Health from $82.00 to $89.00 and gave the company an “overweight” rating in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $88.82.

CVS Health Trading Up 0.4%

CVS Health stock opened at $78.48 on Tuesday. The business has a 50 day moving average price of $76.64 and a two-hundred day moving average price of $69.12. The company has a quick ratio of 0.62, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. The stock has a market cap of $99.62 billion, a price-to-earnings ratio of 206.52, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating the consensus estimate of $1.36 by $0.24. The firm had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, equities analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. CVS Health’s dividend payout ratio is 700.00%.

Insiders Place Their Bets

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.22% of the stock is owned by corporate insiders.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.